- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.81 Å
- Oligo State
- hetero-1-1-1-mer
- Ligands
- 7 x ZN: ZINC ION(Non-covalent)
- 1 x CJD: 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Kung, P.P. et al., Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497). J. Med. Chem. (2018)
- Release Date
- 2017-12-27
- Peptides
- Enhancer of zeste 2 polycomb repressive complex 2 subunit: A
Polycomb protein EED: B
Polycomb protein SUZ12: C - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
BB
EC
S